3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
Specimen Handling
218
Magnetic Resonance Spectroscopy
196
pembrolizumab
188
Carboplatin
163
Biopsy
130
Cisplatin
129
Nivolumab
121
Paclitaxel
110
Cyclophosphamide
107
Radiotherapy
101
Gemcitabine
96
Dexamethasone
89
durvalumab
85
atezolizumab
71
Rituximab
66
Radiation
65
Lenalidomide
64
Doxorubicin
64
Pemetrexed
61
Bevacizumab
59
Etoposide
56
Docetaxel
55
olaparib
53
Ipilimumab
51
Taxes
48
Prednisone
48
Fluorouracil
47
venetoclax
46
Cytarabine
46
Vincristine
45
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
bexmarilimab
×
90 days
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled